Promega Introduces New Mass Spec Reagents, IdeS Protease and Human and Yeast Protein Extracts
![](/46/pdcnewsitem/02/93/41/UqNOEvJJHEaMHsb.jpg)
Promega Corporation announces the launch of new products for scientists working with mass spectrometry. The IdeS Protease enables fast, easy, high performance digestion of immunoglobulin, while the Human and Yeast Protein Extracts provide a test material for optimizing mass spec sample preparation. The new products add to the company’s existing range of proteases and services to improve mass spec sample prep workflows.
IdeS Protease is a recombinant, engineered version of the immunoglobulin-degrading enzyme from Streptococcus pyogenes. It is a highly specific protease that slices Immunoglobulin G (IgG) at a single, targeted site, offering 100% digestion in 30 minutes with no optimization. IdeS can be used to characterize therapeutic antibody candidates using LC/MS, and contains a histidine tag for easy removal. The versatile Promega IdeS enzyme cuts IgGs from a range of species, as well as Fc-fusion proteins.
The new yeast and human protein extracts are designed specifically for mass spectrometry applications. Available in either predigested, cleaned form for immediate use in LC/MS analysis or intact, undigested form to provide a test material for optimizing mass spec protein sample preparation, the extracts provide clean, consistent, quantified, model system samples for LC/MS method development and instrument monitoring. The yeast extracts are beneficial for users who prefer working with a relatively compact and well-studied proteome, whereas the human extract, with large dynamic range, provides the opportunity to work with complex proteomes. The new products are: MS Compatible Yeast Protein Extract, Digest; MS Compatible Human Protein Extract, Digest; MS Compatible Yeast Protein Extract, Intact; and MS Compatible Human Protein Extract, Intact.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance